{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:41:21Z","timestamp":1770482481468,"version":"3.49.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.4158\/ep12303.ra","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T21:08:02Z","timestamp":1381784882000},"page":"1050-1061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes"],"prefix":"10.1016","volume":"19","author":[{"given":"Jaime A.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP12303.RA_bb0010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1210\/en.2008-0945","article-title":"The glucagon-like peptide-1 recep tor regulates endogenous glucose production and mus cle glucose uptake independent of its incretin action","volume":"150","author":"Ayala","year":"2009","journal-title":"Endocrinology"},{"key":"10.4158\/EP12303.RA_bb0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"10.4158\/EP12303.RA_bb0020","series-title":"Presented at: 71st Scientific Sessions of the American Diabetes Assocation","article-title":"Mechanisms of the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes (T2D)","author":"Muscelli","year":"2011"},{"key":"10.4158\/EP12303.RA_bb0025","series-title":"Presented at: 71st Scientific Sessions of the American Diabetes Association","article-title":"Novel biological action of the dipeptidylpeptidase 4 inhibitor, sitagliptin, as a GLP-1 secretagogue","author":"Sangle","year":"2011"},{"key":"10.4158\/EP12303.RA_bb0030","year":"2013"},{"key":"10.4158\/EP12303.RA_bb0035","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4158\/EP12303.RA_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000314690","article-title":"A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes","volume":"86","author":"Fakhoury","year":"2010","journal-title":"Pharmacology"},{"key":"10.4158\/EP12303.RA_bb0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1185\/03007995.2011.554532","article-title":"Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus","volume":"27","author":"Doucet","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0050","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1463-1326.2012.01586.x","article-title":"The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Singh-Franco","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0055","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"Aroda","year":"2012","journal-title":"Clin Ther"},{"key":"10.4158\/EP12303.RA_bb0060","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc06-1120","article-title":"Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis","volume":"29","author":"Bloomgarden","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0065","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0070","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2008-1058090","article-title":"Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus","volume":"40","author":"Fonseca","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12303.RA_bb0080","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"10.4158\/EP12303.RA_bb0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1463-1326.2010.01351.x","article-title":"Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial","volume":"13","author":"Hollander","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0090","series-title":"Presented at: 72nd Scientific Sessions of the American Diabetes Association","article-title":"Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes","author":"Yki-Jarvinen","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0095","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4093\/dmj.2011.35.5.529","article-title":"Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients","volume":"35","author":"Jeon","year":"2011","journal-title":"Diabetes Metab J"},{"key":"10.4158\/EP12303.RA_bb0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2010.01233.x","article-title":"Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study","volume":"12","author":"Matthews","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0110","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.diabres.2011.03.006","article-title":"Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide","volume":"93","author":"Seck","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0115","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1742-1241.2010.02510.x","article-title":"Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial","volume":"64","author":"G\u00f6ke","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0120","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"10.4158\/EP12303.RA_bb0125","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP12303.RA_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164109336038","article-title":"HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?","volume":"6","author":"Reaven","year":"2009","journal-title":"Diab Vasc Dis Res"},{"key":"10.4158\/EP12303.RA_bb0135","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12303.RA_bb0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2337\/dc09-1867","article-title":"Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy","volume":"33","author":"Ahr\u00e9n","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0145","article-title":"Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation","author":"Derosa","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.4158\/EP12303.RA_bb0150","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0029-1234042","article-title":"Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drugna\u00efve patients with type 2 diabetes","volume":"41","author":"Foley","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12303.RA_bb0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/EP12303.RA_bb0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0028-1082334","article-title":"Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drugna\u00efve patients with type 2 diabetes: comparison with metformin","volume":"40","author":"G\u00f6ke","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12303.RA_bb0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1742-1241.2012.02975.x","article-title":"Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension","volume":"66","author":"Gomis","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1463-1326.2008.01021.x","article-title":"Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0175","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1463-1326.2008.00875.x","article-title":"Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia","volume":"10","author":"Scherbaum","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0180","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1742-1241.2010.02353.x","article-title":"Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study","volume":"64","author":"Seck","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0185","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1463-1326.2010.01204.x","article-title":"Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes","volume":"12","author":"Williams-Herman","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.numecd.2009.03.015","article-title":"Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"20","author":"Monami","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.4158\/EP12303.RA_bb0195","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","article-title":"Tolerability of dipeptidyl peptidase-4 inhibitors: a review","volume":"33","author":"Richard","year":"2011","journal-title":"Clin Ther"},{"key":"10.4158\/EP12303.RA_bb0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.4158\/EP12303.RA_bb0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.4158\/EP12303.RA_bb0210","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc10-0482","article-title":"Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis","volume":"33","author":"Garg","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0215","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claimsbased active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6823-8-14","article-title":"Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis","volume":"8","author":"Williams-Herman","year":"2008","journal-title":"BMC Endocr Disord"},{"key":"10.4158\/EP12303.RA_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27 (suppl 3)","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0230","first-page":"1129","article-title":"Prevalence of self-reported cardiovascular disease among persons aged \u226535 years with diabetes--United States, 1997-2005","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4158\/EP12303.RA_bb0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc11-0255","article-title":"A prospective study of the associations between treated diabetes and cancer outcomes","volume":"35","author":"Yeh","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0240","first-page":"207","article-title":"Diabetes and cancer: a consensus report","volume":"60","author":"Giovannucci","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.4158\/EP12303.RA_bb0245","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.30.11.1159","article-title":"Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs","volume":"30","author":"McFarland","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.4158\/EP12303.RA_bb0250","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.25362","article-title":"Risk of cancer in a large cohort of U.S veterans with diabetes","volume":"128","author":"Atchison","year":"2011","journal-title":"Int J Cancer"},{"key":"10.4158\/EP12303.RA_bb0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12303.RA_bb0260","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP12303.RA_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-11-6","article-title":"Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data","volume":"11","author":"Cobble","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP12303.RA_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP12303.RA_bb0275","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12303.RA_bb0280","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12303.RA_bb0285","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"10.4158\/EP12303.RA_bb0290","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0295","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/j.1464-5491.2012.03675.x","article-title":"Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus","volume":"29","author":"Thondam","year":"2012","journal-title":"Diabet Med"},{"key":"10.4158\/EP12303.RA_bb0300","series-title":"SIGN 116. Management of diabetes: a national clinical guideline","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0305","series-title":"Management of diabetes mellitus in primary care (2010)","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0310","series-title":"Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0315","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11892-011-0179-x","article-title":"Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?","volume":"11","author":"Ahr\u00e9n","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.4158\/EP12303.RA_bb0320","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/dc12-0916","article-title":"Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes mellitus: a nationwide population-based study","volume":"36","author":"Hsu","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0325","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/dc10-1915","article-title":"Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes","volume":"34","author":"Johnston","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0330","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrendo.2009.219","article-title":"Diabetes: diabetes therapy and cancer risk","volume":"5","author":"Vigneri","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP12303.RA_bb0335","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"10.4158\/EP12303.RA_bb0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/dmrr.411","article-title":"Allcause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides","volume":"20","author":"Mannucci","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.4158\/EP12303.RA_bb0350","article-title":"Glyburide (generic) prescribing information","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0355","series-title":"Glimepiride (generic) prescribing information","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0360","article-title":"Glipizide (generic) prescribing information","year":"2012"},{"key":"10.4158\/EP12303.RA_bb0365","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007995.2011.599371","article-title":"Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, doseranging comparison with placebo, followed by a long-term extension study","volume":"27","author":"Seino","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0370","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","article-title":"Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study","volume":"63","author":"Nauck","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0375","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2008.01016.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy","volume":"11","author":"Pratley","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0380","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1185\/03007990903156111","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Pratley","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0385","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1210\/jc.2011-2243","article-title":"Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformintreated patients with type 2 diabetes","volume":"97","author":"DeFronzo","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12303.RA_bb0390","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","article-title":"Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"14","author":"Haak","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0395","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of \u03b2\u2013cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0405","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0410","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"key":"10.4158\/EP12303.RA_bb0415","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-na\u00efve patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12303.RA_bb0420","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0425","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12303.RA_bb0430","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1742-1241.2009.02143.x","article-title":"Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial","volume":"63","author":"Chacra","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP12303.RA_bb0435","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1463-1326.2009.01056.x","article-title":"Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial","volume":"11","author":"Jadzinsky","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0440","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0445","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0450","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12303.RA_bb0455","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"key":"10.4158\/EP12303.RA_bb0460","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP12303.RA_bb0465","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes Obes Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2043109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2043109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/T1W2207165226668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:56:03Z","timestamp":1761515763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2043109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1530891X2043109X"],"URL":"https:\/\/doi.org\/10.4158\/ep12303.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP12303.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}